High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease
April 19, 2017 15:26 ET
|
Qu Biologics
VANCOUVER, British Columbia, April 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Jennifer Jaff Center Merges with Patient Advocate Foundation
May 02, 2016 09:14 ET
|
Patient Advocate Foundation
HAMPTON, Va., May 2, 2016 (GLOBE NEWSWIRE) -- The Jennifer Jaff Center, a respected national nonprofit for those suffering from chronic illness, has partnered with Patient Advocate Foundation to...
GENETHERA, INC. ISSUES COMMENTS ON THE FIRST INTERNATIONAL RESEARCH SYMPOSIUM ON MAP AND CROHN'S DISEASE.
September 29, 2015 09:43 ET
|
GeneThera
WESTMINSTER, Colo., Sept. 29, 2015 (GLOBE NEWSWIRE) -- GeneThera, Inc. (OTC: GTHR) as a service to its shareholders and the general public is pleased to release comments on the first Symposium on...
RedHill Biopharma to Host First Quarter 2015 Financial Results Conference Call on April 30, 2015
April 21, 2015 07:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, April 21, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
February 13, 2015 10:18 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Reports Results for the First Quarter of 2014
April 30, 2014 11:00 ET
|
RedHill Biopharma Ltd.
Key financial highlights include:
A first profitable quarter, with net income of $3.4 million, primarily attributed to the $7 million upfront payment received from Salix Pharmaceuticals as part...
Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease
April 28, 2014 21:51 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, April 28, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the...
Mesoblast Reports Strong Half-Year Financial Results
February 25, 2014 17:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results
February 25, 2014 08:00 ET
|
RedHill Biopharma Ltd.
2013 Key Highlights Include:
Strong cash position of over $34 million, as of February 2014, following two private placements in early 2014 and the exercise of warrants, including by directors...
Boardroom Radio Interview with Mesoblast Chief Executive
February 02, 2014 20:06 ET
|
Mesoblast
NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...